Case series on anti-melanoma differentiation-associated gene 5+ dermatomyositis associated with interstitial lung disease

Authors

  • Koya Pranathiya Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telangana, India
  • Are Anusha Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telangana, India
  • Kezia Sam Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telangana, India
  • Anusha Manda Department of Pharmacy Practice, St. Pauls College of Pharmacy, Hyderabad, Telangana, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20230399

Keywords:

DM, Anti-MDA5 , ILD, CADM

Abstract

Dermatomyositis (DM) associated with anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody is a rare autoimmune disease. Anti-MDA5, also known as anti-CADM-140 antibodies. DM affects the skeletal muscle, skin, joints, and lungs and is a form of idiopathic inflammatory myopathy (IIM). All the 5 dermatomyositis MDA5+ positive patients had rapidly progressive interstitial lung disease (RP-ILD). DM is classified into 2 types, classic dermatomyositis (CDM) and clinically amyopathic dermatomyositis (CADM). Anti-MDA5 antibody-positive as RP-ILD without signs of DM or CADM. RP-ILD in patients with CADM associated with antibodies to MDA5 has a high mortality rate. MDA5+ DM is diagnosed by DM rashes (Gottron’s papules or Gottron’s sign and heliotrope rash) and a positive anti-MDA5. RP-ILD includes acute/subacute interstitial pneumonia, which is a progressive deterioration associated with ILD. Immunosuppressives are effective agents for the treatment of anti-MDA5-positive RP-ILD of CADM.

References

Briani C, Doria A, Sarzi-Puttini P. Update on idiopathic inflammatory myopathies. Autoimmunity. 2006;39(3):161-70.

Yoneyama M, Kikuchi M, Matsumoto K. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol. 2005;175(5):2851-8.

Kato H, Takeuchi O, Sato S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441(1):101-5.

Chitnis T, Khoury SJ. 20 Immunologic neuromuscular disorders. J Allergy Clin Immunol. 2003;111(2):S659-68.

Sato S, Hirakata M, Kuwana M. Autoantibodies to a, 140-kd polypeptide,CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571-6.

Sakamoto N, Ishimoto H, Nakashima S, Yura H, Miyamura T, Okuno D, et al. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis. Intern Med. 2019;58:837-41.

Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T, et al. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology. 2010;49:1726-33.

Chen Z, Cao M, Plana MN. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res. 2013;65:1316-24.

Koga T, Fujikawa K, Horai Y. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology. 2012;51:1278-84.

Moghadam-Kia S, Oddis CV, Sato S. Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in north American patients with dermatomyositis. J Rheumatol. 2017;44:319-25.

Wanlong W, Danting Z, Li GZ. Interstitial Lung disease in Anti-MDA5+ Dermatomyositis. Immunology. 2021.

Hoshino SSK, Satoh T. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2009;60:2193-200.

Nakashima R, Imura Y, Kobayashi S. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen recognized by anti-CADM-140 antibody. Rheumatology. 2010;49:433-40.

Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwa-moto N, et al. The diagnostic utility of anti-melanoma diferentiation-associated gene 5 antibody testing for predict-ing the prognosis of Japanese patients with DM. Rheumatology. 2012;51(7):1278-84.

Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14:337-45.

Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403-7.

Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344-7.

Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF. Cutaneous ulceration in dermatomyositis: Association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res (Hoboken). 2015;67:667-72.

Gerami P, Schope J, McDonald L, Walling H, Sontheimer R. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine ́ myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54:597-613.

Ye Y, Fu Q, Wang R. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease. J Clin Lab Anal. 2019;33:e22978.

Kaieda S, Gono T, Masui K. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease. PLoS one. 2020;15:e0234523.

Chen Z, Cao M, Plana MN. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res. 2013;65:1316-24.

Koichi Y, Aya Y, Megumi U, Shunichi K, Masafumi S, Hiroaki M. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol. 2017;27(3):536-40.

Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65:25-34.

Muro Y, Sugiura K, Akiyama M. Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review. Clin Rev Allergy Immunol. 2016;51(3):293-302.

Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32(9):1719-26.

Downloads

Published

2023-02-22

How to Cite

Pranathiya, K., Anusha, A., Sam, K., & Manda, A. (2023). Case series on anti-melanoma differentiation-associated gene 5+ dermatomyositis associated with interstitial lung disease. International Journal of Basic & Clinical Pharmacology, 12(2), 264–267. https://doi.org/10.18203/2319-2003.ijbcp20230399